Evaluating a new treatment for Cushing disease using seliciclib
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)
This study is looking at how well a new medication called seliciclib works for people with Cushing disease by helping to lower hormone levels and improve symptoms, while also keeping an eye on safety and any side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10916162 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of seliciclib, a small molecule that inhibits specific proteins involved in hormone production, for treating patients with Cushing disease. Cushing disease is caused by a tumor in the pituitary gland that leads to excessive hormone secretion, resulting in serious health issues. The study aims to determine the safety and efficacy of different doses of seliciclib in controlling hormone levels and alleviating symptoms associated with this rare condition. Patients will be monitored for improvements in their health and any potential side effects from the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Cushing disease who have not responded adequately to existing treatments.
Not a fit: Patients who do not have Cushing disease or those who have already achieved control of their condition through other therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective medical therapy for patients suffering from Cushing disease, potentially reducing their morbidity and mortality.
How similar studies have performed: Preliminary data from earlier studies have shown promise for seliciclib, indicating that this approach may be effective, although it is still being evaluated in a larger trial.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Melmed, Shlomo — Cedars-Sinai Medical Center
- Study coordinator: Melmed, Shlomo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.